Document Detail


Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation.
MedLine Citation:
PMID:  10568659     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ventricular tachycardia, which causes hemodynamic instability, and ventricular fibrillation do not occur frequently in any hospital. However, they usually occur in patients who have severe underlying cardiovascular disease such as myocardial ischemia/infarction or congestive heart failure, and they are associated with high mortality. Most of those deaths are due to an intractable arrhythmia, not suppressible with even the most potent antiarrhythmic drugs. Fortunately, during the last few years, our ability to suppress highly lethal ventricular arrhythmia has been enhanced by the approval of intravenous amiodarone. When used in appropriate patient populations, intravenous amiodarone has been successful in suppressing the most malignant arrhythmia, thus permitting aggressive and successful treatment of severe underlying cardiac conditions. This article reviews data on the use of parenteral antiarrhythmic drugs for the control of ventricular arrhythmia in patients in hospital, and will attempt to provide some guidance as to how these antiarrhythmic drugs may be used in specific patient populations to maximize their efficacy and safety. We will also make recommendations on the sequence of therapy for specific arrhythmias to optimize the chances of patient survival.
Authors:
P R Kowey; R A Marinchak; S J Rials; D B Bharucha
Related Documents :
9403159 - Cellular electrophysiologic mechanisms of cardiac arrhythmias.
15066909 - Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrin...
22714549 - Optimal timing for first-pass stress ct myocardial perfusion imaging.
20930959 - A review of the mechanisms of ventricular arrhythmia in brugada syndrome.
6686539 - Arrhythmia and prognosis in hypertrophic cardiomyopathy.
14501159 - Effect of the sarcolemmal k(atp) channel blocker hmr1098 on arrhythmias induced by prog...
8293649 - Angiographic prediction of dissection followed by ischaemic complications during corona...
1879219 - Verapamil and ventricular tachycardias.
22655489 - The effects on cordal and leaflet stiffness of severe apical, posterior, and outward pa...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  84     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1999 Nov 
Date Detail:
Created Date:  1999-12-01     Completed Date:  1999-12-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  46R-51R     Citation Subset:  AIM; IM    
Affiliation:
Cardiovascular Division, Lankenau Hospital and Medical Research Center, Main Line Health System, Wynnewood, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amiodarone / administration & dosage*,  adverse effects,  pharmacokinetics
Anti-Arrhythmia Agents / administration & dosage*,  adverse effects,  pharmacokinetics
Dose-Response Relationship, Drug
Drug Administration Schedule
Hemodynamics / drug effects
Hospitalization*
Humans
Infusions, Intravenous
Tachycardia, Ventricular / blood,  drug therapy*,  etiology
Ventricular Fibrillation / blood,  drug therapy*,  etiology
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.
Next Document:  Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias...